Abstract
Background: Domino transplant occurs when a recipient explanted graft is used for a second recipient.
Introduction: The first experience came from thoracic surgery by the observation that many patients during heart-lung transplantation actually showed a functional heart that could be employed in other subjects with a good result.
Results: This concept was then extended to the field of liver transplantation. At present, some patients transplanted for an inborn metabolic disease may be considered as excellent domino liver donors.
Conclusion: The results, limitations, clinical challenges and the donor and recipient features of domino liver transplantation are discussed in this manuscript.
Keywords: Amyloidosis transthyretin, domino, human, inborn disease, liver, transplantation.
Graphical Abstract
[1]
Klepetko W, Wollenek G, Laczkovics A, Laufer G, Wolner E. Domino transplantation of heart-lung and heart: An approach to overcome the scarcity of donor organs. J Heart Lung Transplant 1991; 10: 129-31.
[2]
Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010; 15: 269-76.
[3]
Hemming AW, Cattral MS, Greig PD, et al. Domino liver transplantation for familial amyloid polyneuropathy: optimal use of a scarce resource. Transplant Proc 1999; 31: 515.
[4]
Furtado AJL. Domino liver transplantation using livers from patients with familial amyloidotic polyneuropathy. Curr Opin Organ Transplant 2000; 5: 69-73.
[5]
Familial Amyloidotic Polyneuropathy World Transplant registry and Domino Liver Transplant Registry. Available from
http: //www.fapwtr.org/.
[6]
Geyer ED, Burrier C, Tumin D, et al. Outcomes of domino liver transplantation compared to deceased donor liver transplantation: A propensity-matching approach. Transpl Int 2018; 31: 1200-6.
[7]
Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-62.
[8]
Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995; 60: 512-21.
[9]
Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847-54.
[10]
Coelho LF, Martins da Silva A, Waddington CM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012; 79: 785-92.
[11]
Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29(Suppl. 1): S3-S13.
[12]
Berk JL, Suhr OB, Sekijima Y, et al. The diflunisal trial: Study accrual and drug tolerance. Amyloid 2012; 19(Suppl. 1): 37-8.
[13]
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.
[14]
Hellman U, Alarcon F, Lundgren H-E, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15: 181-6.
[15]
Marín-Gómez LM, Gómez-Bravo MÁ, Barrera-Pulido L, et al. Outcomes of domino liver transplantation: A single institution’s experience. Transplant Proc 2010; 42: 644-6.
[16]
Bispo M, Marcelino P, Marques HP, et al. Domino versus deceased donor liver transplantation: Association with early graft function and perioperative bleeding. Liver Transpl 2011; 17: 270-8.
[17]
Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999; 189: 584-93.
[18]
Schmidt HH, Nashan B, Pröpsting MJ, et al. Familial Amyloidotic Polyneuropathy: Domino liver transplantation. J Hepatol 1999; 30: 293-8.
[19]
Bittencourt PL, Couto CA, Leitão RMC, et al. No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid 2002; 9: 194-6.
[20]
Furtado AJ. Domino liver transplantation using FAP grafts. HUC experience--hopes and realities. Amyloid 2003; 10(Suppl. 1): 84-7.
[21]
Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
[22]
Barreiros A-P, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: A single-center experience. Liver Transpl 2010; 16: 314-23.
[23]
Abdelfatah MM, Hayman SR, Gertz MA. Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid 2014; 21: 136-7.
[24]
Misumi Y, Oshima T, Ueda M, et al. Occurrence factors and clinical picture of iatrogenic transthyretin amyloidosis after domino liver transplantation Amyloid 2017; 24(sup1). : 123-4.
[25]
Mnatsakanova D, Živković SA. Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol 2017; 9: 126-30.
[26]
Adams D, Lacroix C, Antonini T, et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid 2011; 18(Suppl. 1): 174-7.
[27]
Dixit N, Castano A, Farr MJ, et al. Rapidly progressive transthyretin-mediated amyloidosis in a domino liver transplant recipient of a Ser23Asn donor. J Clin Neuromuscul Dis 2016; 17: 142-5.
[28]
Misumi Y, Narita Y, Oshima T, et al. Recipient aging accelerates acquired transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2016; 22: 656-64.
[29]
Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23: 209-13.
[30]
Bourque PR, Shafi S, Jansen GH, McCurdy A, Warman Chardon J. Amyloid neuropathy following domino liver transplantation: Response to diflunisal. JAMA Neurol 2016; 73: 477-8.
[31]
Vieira H, Rodrigues C, Pereira L, et al. Liver retransplantation in patients with acquired familial amyloid polyneuropathy: A portuguese center experience. Transplant Proc 2015; 47: 1012-5.
[32]
Antonini TM, Lozeron P, Lacroix C, et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant 2013; 13: 2734-8.
[33]
Nunes F, Valente M, Pereira R, Amil M. Domino liver transplant: Influence on the number of donors and transplant coordination. Transplant Proc 2004; 36: 916-7.
[34]
Chuang DT. Maple syrup urine disease: It has come a long way. J Pediatr 1998; 132(3 Pt 2): S17-23.
[35]
Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: Clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 1994; 79(1-2): 21-45.
[36]
Strauss KA, Mazariegos GV, Sindhi R, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant 2006; 6: 557-64.
[37]
Barshop BA, Khanna A. Domino hepatic transplantation in maple syrup urine disease. N Engl J Med 2005; 353: 2410-1.
[38]
Khanna A, Hart M, Nyhan WL, et al. Domino liver transplantation in maple syrup urine disease. Liver Transpl 2006; 12: 876-82.
[39]
Mohan N, Karkra S, Rastogi A, Vohra V, Soin AS. Living donor liver transplantation in maple syrup urine disease - Case series and world’s youngest domino liver donor and recipient. Pediatr Transplant 2016; 20: 395-400.
[40]
Roda KMO, Vincenzi R, Fonseca EA, et al. Domino liver transplant in maple syrup urine disease. Transplantation 2019; 103(3): 536-43.
[41]
Bilheimer DW, Stone NJ, Grundy SM. Metabolic studies in familial hypercholesterolemia. J Clin Invest 1979; 64: 524-33.
[42]
Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004; 15: 413-22.
[43]
Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658-64.
[44]
Popescu I, Simionescu M, Tulbure D, et al. Homozygous familial hypercholesterolemia: Specific indication for domino liver transplantation. Transplantation 2003; 76(9): 1345-50.
[45]
Liu C, Loong C-C, Hsia C-Y, et al. Venoplasty of hepatic venous outflow with a venous patch in domino liver transplantation. Liver Transpl 2008; 14: 1378-9.
[46]
Liu C, Niu D-M, Loong C-C, et al. Domino liver graft from a patient with homozygous familial hypercholesterolemia. Pediatr Transplant 2010; 14: E30-3.
[47]
Popescu I, Habib N, Dima S, et al. Domino liver transplantation using a graft from a donor with familial hypercholesterolemia: Seven-yr follow-up. Clin Transplant 2009; 23: 565-70.
[48]
Golbus JR, Farhat L, Fontana RJ, Rubenfire M. Rapidly progressive atherosclerosis after domino liver transplantation from a teenage donor with homozygous familial hypercholesterolemia. J Clin Lipidol 2017; 11: 1284-8.
[49]
Danpure CJ. Molecular and clinical heterogeneity in primary hyperoxaluria type 1. Am J Kidney Dis 1991; 17: 366-9.
[50]
Danpure CJ, Smith LH. The primary hyperoxalurias. Kidney stones Med Surg Manag 1996; 1996 : 859 -1 .
[51]
Jamieson NV, Jamieson KA. Primary hyperoxaluria Type 1: Gene therapy by liver transplantation. Transplantation 2009; 87: 1273-4.
[52]
Donckier V, El Nakadi I, Closset J, et al. Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria. Transplantation 2001; 71: 1346-8.
[53]
Saner FH, Treckmann J, Pratschke J, et al. Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1. Transplantation 2010; 90: 782-5.
[54]
Casas-Melley AT, Thomas PG, Krueger LJ, et al. Domino as a bridge to definitive liver transplantation in a neonate. Pediatr Transplant 2002; 6: 249-54.
[55]
Chapman KA, Summar ML. Propionic acidemia consensus conference summary. Mol Genet Metab 2012; 105: 3-4.
[56]
Barshes NR, Vanatta JM, Patel AJ, et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: A comprehensive review. Pediatr Transplant 2006; 10: 773-81.
[57]
Vara R, Turner C, Mundy H, et al. Liver transplantation for propionic acidemia in children. Liver Transpl 2011; 17: 661-7.
[58]
Moguilevitch M, Delphin E. Domino liver transplantation from a child with propionic acidemia to a child with idiopathic fulminant hepatic failure. Case Rep Transplant 2018; 2018: 1-3.
[59]
Govil S, Shanmugam NP, Reddy MS, Narasimhan G, Rela M. A metabolic chimera: Two defective genotypes make a normal phenotype. Liver Transpl 2015; 21: 1453-4.
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
35
3